Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pagoclone Indevus.

Alan Bateson1

  • 1School of Biomedical Sciences, Leeds University, Leeds, LS2 9JT, UK. a.n.bateson@leeds.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|March 11, 2003
PubMed
Summary

Pagoclone, a GABA-A receptor modulator, was investigated for panic and anxiety disorders. Despite initial trials, development was discontinued by Pfizer in 2002.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benzodiazepines: risks and benefits. A reconsideration.

Journal of psychopharmacology (Oxford, England)·2013
See all related articles

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Pagoclone is a cyclopyrrolone compound.
  • It acts as a GABAA receptor modulator.
  • Investigated for potential therapeutic applications in anxiety and panic disorders.

Purpose of the Study:

  • To evaluate the efficacy and safety of pagoclone.
  • To assess its potential as a treatment for panic and anxiety disorders.

Main Methods:

  • Phase II/III clinical trials initiated by Indevus in 1996.
  • Phase III trial for panic disorder initiated by Pfizer in 2000.

Main Results:

  • Development of pagoclone was discontinued by Pfizer in June 2002.
  • No specific efficacy or safety results are detailed in the provided abstract.

Conclusions:

  • The development of pagoclone for panic and anxiety disorders was halted.
  • Further research or development by Pfizer did not proceed beyond the trial phase.